The impact of adding hp-hMG in r-FSH started GnRH antagonist cycles on ART outcome

References

• Kobayashi M, Nakano R, Ooshima A. Immunohistochemical localization of pituitary gonadotrophins and gonadal steroids confirms the ‘two-cell, two-gonadotrophin’ hypothesis of steroidogenesis in the human ovary. J Endocrinol. 1990;126:483–488.
   PubMed Web of Science ®Google Scholar
• Hillier SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol. 2001;179:39–46.
   PubMed Web of Science ®Google Scholar
• Doody K, Devroey P, Gordon K, et al. LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles. Reprod Biomed Online. 2010;20:565–567.
   PubMed Web of Science ®Google Scholar
• Fischer R. Understanding the role of LH: myths and facts. Reprod Biomed Online. 2007;15:468–477.
   PubMed Web of Science ®Google Scholar
• Marrs R, Meldrum D, Muasher S, et al. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online. 2004;8:175–182.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum M, Bungum L, et al. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed. 2004;8:635–643.
   PubMed Web of Science ®Google Scholar
• Bosch E, Labarta E, Crespo J, et al. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril. 2011;95:1031–1036.
   PubMed Web of Science ®Google Scholar
• Fabregues F, Creus M, Penarrubia J, et al. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in downregulated women of advanced reproductive age. Fertil Steril. 2006;85:925–931.
   PubMed Web of Science ®Google Scholar
• NyboeAndersen A, Humaidan P, Fried G, et al. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod. 2007;23:427–434.
   PubMed Web of Science ®Google Scholar
• Sonmezer M, Duvan CI, Ozmen B, et al. Outcomes after early or midfollicular phase LH supplementation in previous inadequate responders. Reprod Biomed. 2010;20:350–357.
   PubMed Web of Science ®Google Scholar
• Hardarson T, Hanson C, Sjögren A, et al. Human embryos with unevenly sized blastomeres have lower pregnancy and implantation rates: indications for aneuploidy and multinucleation. Hum Reprod. 2001;16:313–318.
   PubMed Web of Science ®Google Scholar
• Balasch J, Fábregues F, Carmona F, et al. Ovarian luteinizing hormone priming preceding follicle-stimulating hormone stimulation: clinical and endocrine effects in women with long-term hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2009;94:2367–2373.
   PubMed Web of Science ®Google Scholar
• Franco JG, Baruffi RL, Oliveira JB, et al. Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study. Reprod Biol Endocrinol. 2009;7:58.
   PubMed Web of Science ®Google Scholar
• Odell WD, Griffin J. Pulsatile secretion of human chorionic gonadotropin in normal adults. N Engl J Med. 1987;317:1688–1691.
   PubMed Web of Science ®Google Scholar
• Choi J, Smitz J. Luteinizing hormone and human chorionic gonadotropin: distinguishing unique physiologic roles. Gynecol Endocrinol. 2014;30:177–181.
   Web of Science ®Google Scholar
• Cole LA. New discoveries on the biology and detection of human chorionic gonadotropin. Reprod Biol Endocrinol. 2009;7:8–44.
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Zikopoulos K, Schiettecatte J, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod. 2004;19:2490–2496.
   PubMed Web of Science ®Google Scholar
• Levi-Setti PE, Cavagna M, Bulletti C. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH. Eur J Obstet Gynecol Reprod Biol. 2006;126:212–216.
   PubMed Web of Science ®Google Scholar
• Zygmunt M, Herr F, Keller-Schoenwetter S, et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab. 2002;87:5290–5296.
   PubMed Web of Science ®Google Scholar
• Rashidi B, Soleimani RJ, Roshangar L, et al. Evaluation of pinopodes expression on the mouse endometrium immediately before implantation by treatment with HMG/HCG and sildenafil citrate administration. Iran J Basic Med Sci. 2012;15:1091–1096.
   PubMed Web of Science ®Google Scholar
• Grondahl ML, Borup R, Lee YB, et al. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin. Fertil Steril. 2009;91:1820–1830.
   PubMed Web of Science ®Google Scholar
• Mochtar MH, Van der Veen F, Ziech M, et al. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2007;18:CD005070.
   Google Scholar
• Lehert P, Kolibianakis EM, Venetis CA, et al. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol. 2014;20:17.
   Web of Science ®Google Scholar
• Fabregues F, Iraola A, Casals G, et al. Evaluation of two doses of recombinant human luteinizing hormone supplementation in down-regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. Eur J Obstet Gynecol Reprod Biol. 2011;158:56–61.
   PubMed Web of Science ®Google Scholar
• Musters AM, Van Wely M, Mastenbroek S, et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Hum Reprod. 2012;27:244–250.
   PubMed Web of Science ®Google Scholar
• Requena A, Cruz M, Ruiz FJ, et al. Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin. Reprod Biol Endocrinol. 2014;12:10.
   PubMed Web of Science ®Google Scholar
• Pacchiarotti A, Sbracia M, Frega A, et al. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril. 2010;94:2467–2469.
   PubMed Web of Science ®Google Scholar
• Buhler KF, Fischer R. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case control study. Gynecol Endocrinol. 2011;28:345–350.
   PubMed Web of Science ®Google Scholar
• Andersen CY, Elbaek HO, Alsbjerg B, et al. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. Hum Reprod. 2015;30:2387–2395.
   PubMed Web of Science ®Google Scholar